And given AbbVie's rich pipeline -- with 21 phase 3 studies and many more early-stage clinical trials -- the company is well-positioned to add more products to replace Humira. AbbVie is here to stay An excellent dividend track record, coupled with a deep lineup and solid pipeline, makes the company an outstanding dividend-paying stock to help you smooth out the harmful effects of inflation. There are plenty of excellent dividend stocks on the market; one great option to consider is pharma giant AbbVie (NYSE: ABBV).